



## Living Cell Technologies Limited

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQX:** LVCLY

### ASX ANNOUNCEMENT

## LCT founder Sir Robert Elliott dies

*Scientific entrepreneur was at the forefront of health research in New Zealand*

---

**21 August 2020 – Auckland** – Living Cell Technologies (LCT) founder, Emeritus Professor Sir Robert Elliott, has died aged 86.

Chairman Dr Bernie Tuch today paid tribute to one of the country's foremost scientific entrepreneurs.

"The medical, scientific and biotechnology communities in New Zealand have lost a tireless researcher and a visionary pioneer," said Dr Tuch. "All of us at LCT are saddened to hear of his death.

"Long before Bob founded LCT, he was at the forefront of child health research in New Zealand.

"His research into cystic fibrosis and type 1 diabetes was world renowned and he contributed to other biotechnology success stories including A2 Corporation and Somnaceutics."

Sir Robert trained as a paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. A world leader in diabetes and autoimmune related research, he published more than 200 research papers and was an Emeritus Professor of Child Health Research.

Sir Robert received his knighthood in June 2020 for services to medical research. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award. In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community.

He was on the board of Cure Kids, Wings Trust and was patron of the NZ Cystic Fibrosis Foundation. He was also a director of Breathe Easy Limited, Kopu Limited, Visregen Technologies Limited, Fac8 Limited and NZeno Limited.

Sir Robert co-founded Living Cell Technologies (initially called Diatranz) with Auckland businessman David Collinson in 1987 aiming to commercialise his research into type 1 diabetes.

"Bob leaves an incredible legacy," said Dr Tuch, "one we are humbled to be a part of. We were fortunate to have Bob on the board right up until his death. At 86 years of age he was still coming up with new ideas.

"Bob will be sorely missed; it was an honour to work with him," he added.

Bob is survived by his wife of more than 60 years, Betsy, their five children and 11 grandchildren.

The required Appendix 3Z is attached.

Authorised for release by the board of LCT.

**-ends-**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<b>At the Company:</b> Ken Taylor Chief Executive Mobile: +64 21 796 000 <a href="mailto:ktaylor@lctglobal.com">ktaylor@lctglobal.com</a>	<b>Media Contact:</b> Rachael Joel Botica Butler Raudon Partners Mobile: +64 21 403 504 <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a>
---	--

### **About Living Cell Technologies**

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter.

### **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>LIVING CELL TECHNOLOGIES LIMITED</b>
<b>ABN</b>	<b>14 104 028 042</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Robert Bartlett Elliott
<b>Date of last notice</b>	13 December 2018
<b>Date that director ceased to be director</b>	21 August 2020

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
5,109,269 ordinary shares
600,000 unlisted options

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	
Nil	

### Part 3 – Director's interests in contracts

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

---

+ See chapter 19 for defined terms.